Current Price Disclosure cycle – 2025 April
Page last updated: 28 March 2025
The 2025 April cycle has a data collection period of 1 April 2024 to 30 September 2024.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 November 2024.
The reduction day is 1 April 2025.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
Contents
- Outcomes of Price Disclosure calculations
- Indicative prices of brands scheduled for a price disclosure reduction
- Confirmed prices of brands scheduled for a price disclosure reduction
- Brand price reductions and savings to patients
Outcomes of Price Disclosure calculations
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health and Aged Care. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations have been published in a legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their December 2024 PBS approved ex‑manufacturer price (AEMP) and the weighted average disclosed price (WADP) was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2024 will also take the reduction on 1 April 2025 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute was 14 January 2025.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is presented in the table below.
Legal Instrument Drug |
Legal Instrument Form |
Legal Instrument MoA |
Brands of PI designated brands under 99ADHC (Y/N) |
Floor Price |
Price reduction applied in 2 previous cycles (Y/N) |
Average Unadjusted Price Reduction (UPR) exceeds 12.5% over 3 cycles (Y/N) |
December 2024 AEMP |
April 2025 AEMP |
Percentage difference between December 2024 and April 2025 AEMP (%) |
UPR threshold (%) |
Calculations based on: |
---|---|---|---|---|---|---|---|---|---|---|---|
Adalimumab |
Injection 20 mg in 0.4 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$309.45 |
$272.84 |
11.83% |
10% |
GWAPD |
Adalimumab |
Injection 40 mg in 0.4 mL pre-filled pen |
Injection |
N |
- |
- |
- |
$505.95 |
$444.17 |
12.21% |
10% |
GWAPD |
Azacitidine |
Powder for injection 100 mg |
Injection |
Y |
$40.79 |
N |
Y |
$40.79 |
$25.69 |
37.02% |
30% |
OWAPD |
Bevacizumab |
Solution for I.V. infusion 100 mg in 4 mL |
Injection |
N |
- |
- |
- |
$61.77 |
$53.82 |
12.87% |
10% |
OWAPD |
Bevacizumab |
Solution for I.V. infusion 400 mg in 16 mL |
Injection |
N |
- |
- |
- |
$247.07 |
$215.28 |
12.87% |
10% |
OWAPD |
Bortezomib |
Powder for injection 2.5 mg |
Injection |
N |
- |
- |
- |
$28.47 |
$24.92 |
12.47% |
10% |
GWAPD |
Bortezomib |
Powder for injection 3.5 mg |
Injection |
N |
- |
- |
- |
$39.85 |
$34.88 |
12.47% |
10% |
GWAPD |
Bortezomib |
Solution for injection 2.5 mg in 1 mL |
Injection |
N |
- |
- |
- |
$28.47 |
$24.92 |
12.47% |
10% |
GWAPD |
Bortezomib |
Solution for injection 3.5 mg in 1.4 mL |
Injection |
N |
- |
- |
- |
$39.85 |
$34.88 |
12.47% |
10% |
GWAPD |
Carvedilol |
Tablet 12.5 mg |
Oral |
Y |
$5.05 |
N |
Y |
$5.05 |
$4.00 |
20.79% |
10% |
GWAPD |
Carvedilol |
Tablet 25 mg |
Oral |
Y |
$6.31 |
N |
Y |
$6.31 |
$4.79 |
24.09% |
10% |
GWAPD |
Carvedilol |
Tablet 6.25 mg |
Oral |
Y |
$4.04 |
N |
Y |
$4.04 |
$4.00 |
0.99% |
10% |
GWAPD |
Cinacalcet |
Tablet 30 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$23.72 |
$19.75 |
16.74% |
10% |
GWAPD |
Cinacalcet |
Tablet 60 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$47.44 |
$39.51 |
16.72% |
10% |
GWAPD |
Cinacalcet |
Tablet 90 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$71.16 |
$59.26 |
16.72% |
10% |
GWAPD |
Clomipramine |
Tablet containing clomipramine hydrochloride 25 mg |
Oral |
Y |
$5.52 |
N |
Y |
$5.52 |
$4.65 |
15.76% |
10% |
GWAPD |
Cyclophosphamide |
Powder for injection 2 g (anhydrous) |
Injection |
N |
- |
- |
- |
$37.18 |
$31.20 |
16.08% |
10% |
OWAPD |
Dabigatran etexilate |
Capsule 110 mg (as mesilate) |
Oral |
N |
- |
- |
- |
$6.19 |
$5.53 |
10.66% |
10% |
OWAPD |
Dabigatran etexilate |
Capsule 150 mg (as mesilate) |
Oral |
N |
- |
- |
- |
$36.88 |
$32.94 |
10.68% |
10% |
OWAPD |
Dasatinib |
Tablet 100 mg |
Oral |
N |
- |
- |
- |
$1,197.56 |
$1,019.07 |
14.90% |
10% |
OWAPD |
Dasatinib |
Tablet 20 mg |
Oral |
N |
- |
- |
- |
$727.08 |
$618.71 |
14.90% |
10% |
OWAPD |
Dasatinib |
Tablet 50 mg |
Oral |
N |
- |
- |
- |
$1,197.56 |
$1,019.07 |
14.90% |
10% |
OWAPD |
Dasatinib |
Tablet 70 mg |
Oral |
N |
- |
- |
- |
$1,482.66 |
$1,261.67 |
14.90% |
10% |
OWAPD |
Deferasirox |
Tablet 180 mg |
Oral |
N |
- |
- |
- |
$60.54 |
$29.02 |
52.06% |
10% |
GWAPD |
Deferasirox |
Tablet 360 mg |
Oral |
N |
- |
- |
- |
$121.09 |
$58.04 |
52.07% |
10% |
GWAPD |
Deferasirox |
Tablet 90 mg |
Oral |
N |
- |
- |
- |
$30.27 |
$14.51 |
52.06% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$91.60 |
$71.24 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$103.62 |
$80.59 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$129.53 |
$100.74 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$33.58 |
$26.12 |
22.22% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$37.53 |
$29.19 |
22.22% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$64.97 |
$50.53 |
22.23% |
10% |
GWAPD |
Enoxaparin |
Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$69.08 |
$53.72 |
22.24% |
10% |
GWAPD |
Erlotinib |
Tablet 100 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$460.68 |
$379.60 |
17.60% |
10% |
OWAPD |
Erlotinib |
Tablet 150 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$569.91 |
$469.61 |
17.60% |
10% |
OWAPD |
Erlotinib |
Tablet 25 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$126.93 |
$104.59 |
17.60% |
10% |
OWAPD |
Esomeprazole and clarithromycin and amoxicillin |
Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) |
Oral |
N |
- |
- |
- |
$23.65 |
$20.69 |
12.52% |
10% |
OWAPD |
Esomeprazole and clarithromycin and amoxicillin |
Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) |
Oral |
N |
- |
- |
- |
$23.65 |
$20.69 |
12.52% |
10% |
OWAPD |
Exemestane |
Tablet 25 mg |
Oral |
Y |
$42.25 |
N |
Y |
$42.25 |
$35.19 |
16.71% |
10% |
GWAPD |
Fulvestrant |
Injection 250 mg in 5 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$164.59 |
$134.60 |
18.22% |
10% |
GWAPD |
Gabapentin |
Tablet 600 mg |
Oral |
Y |
$23.12 |
N |
Y |
$23.12 |
$19.16 |
17.13% |
10% |
GWAPD |
Ganirelix |
Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$24.77 |
$22.10 |
10.78% |
10% |
GWAPD |
Lamotrigine |
Tablet 5 mg |
Oral |
Y |
$5.88 |
N |
Y |
$5.88 |
$4.79 |
18.54% |
10% |
GWAPD |
Lansoprazole |
Capsule 30 mg |
Oral |
Y |
$4.48 |
N |
Y |
$4.48 |
$4.00 |
10.71% |
10% |
GWAPD |
Lansoprazole |
Tablet 30 mg (orally disintegrating) |
Oral |
Y |
$4.48 |
N |
Y |
$4.48 |
$4.00 |
10.71% |
10% |
GWAPD |
Lenalidomide |
Capsule 10 mg |
Oral |
N |
- |
- |
- |
$669.88 |
$548.44 |
18.13% |
10% |
OWAPD |
Lenalidomide |
Capsule 15 mg |
Oral |
N |
- |
- |
- |
$806.80 |
$660.53 |
18.13% |
10% |
OWAPD |
Lenalidomide |
Capsule 25 mg |
Oral |
N |
- |
- |
- |
$1,055.57 |
$864.20 |
18.13% |
10% |
OWAPD |
Lenalidomide |
Capsule 5 mg |
Oral |
N |
- |
- |
- |
$511.34 |
$418.64 |
18.13% |
10% |
OWAPD |
Levodopa with carbidopa and entacapone |
Tablet 100 mg-25 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$67.44 |
$56.96 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 125 mg-31.25 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$70.00 |
$59.12 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 150 mg-37.5 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$73.82 |
$62.35 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 200 mg-50 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$79.69 |
$67.31 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 50 mg-12.5 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$61.06 |
$51.57 |
15.54% |
10% |
GWAPD |
Levodopa with carbidopa and entacapone |
Tablet 75 mg-18.75 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$63.86 |
$53.94 |
15.53% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 100 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$9.73 |
$8.32 |
14.49% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 125 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$12.49 |
$10.68 |
14.49% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 200 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$11.41 |
$9.76 |
14.46% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 50 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$9.39 |
$8.03 |
14.48% |
10% |
GWAPD |
Levothyroxine |
Tablet containing 75 micrograms anhydrous levothyroxine sodium |
Oral |
N |
- |
- |
- |
$9.55 |
$8.17 |
14.45% |
10% |
GWAPD |
Lurasidone |
Tablet containing lurasidone hydrochloride 40 mg |
Oral |
N |
- |
- |
- |
$18.99 |
$14.52 |
23.54% |
10% |
GWAPD |
Lurasidone |
Tablet containing lurasidone hydrochloride 80 mg |
Oral |
N |
- |
- |
- |
$37.97 |
$29.04 |
23.52% |
10% |
GWAPD |
Mefenamic acid |
Capsule 250 mg |
Oral |
N |
- |
- |
- |
$5.79 |
$4.56 |
21.24% |
10% |
GWAPD |
Morphine |
Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL |
Injection |
N |
- |
- |
- |
$4.42 |
$3.85 |
12.90% |
10% |
OWAPD |
Morphine |
Injection containing morphine hydrochloride trihydrate 20 mg in 1 mL |
Injection |
N |
- |
- |
- |
$6.77 |
$5.89 |
13.00% |
10% |
OWAPD |
Naltrexone |
Tablet containing naltrexone hydrochloride 50 mg |
Oral |
N |
- |
- |
- |
$85.54 |
$76.68 |
10.36% |
10% |
OWAPD |
Nebivolol |
Tablet 1.25 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$9.78 |
$8.59 |
12.17% |
10% |
GWAPD |
Nebivolol |
Tablet 10 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$27.60 |
$24.24 |
12.17% |
10% |
GWAPD |
Nebivolol |
Tablet 5 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$24.42 |
$21.44 |
12.20% |
10% |
GWAPD |
Perindopril |
Tablet containing perindopril arginine 10 mg |
Oral |
Y |
$4.07 |
N |
Y |
$4.07 |
$4.00 |
1.72% |
10% |
GWAPD |
Perindopril |
Tablet containing perindopril erbumine 8 mg |
Oral |
Y |
$4.07 |
N |
Y |
$4.07 |
$4.00 |
1.72% |
10% |
GWAPD |
Sildenafil |
Tablet 20 mg (as citrate) |
Oral |
Y |
$131.30 |
N |
Y |
$131.30 |
$95.81 |
27.03% |
10% |
GWAPD |
Sitagliptin |
Tablet 100 mg |
Oral |
N |
- |
- |
- |
$22.93 |
$19.33 |
15.70% |
10% |
OWAPD |
Sitagliptin |
Tablet 25 mg |
Oral |
N |
- |
- |
- |
$22.93 |
$19.33 |
15.70% |
10% |
OWAPD |
Sitagliptin |
Tablet 50 mg |
Oral |
N |
- |
- |
- |
$22.93 |
$19.33 |
15.70% |
10% |
OWAPD |
Sunitinib |
Capsule 12.5 mg |
Oral |
N |
- |
- |
- |
$581.73 |
$513.55 |
11.72% |
10% |
OWAPD |
Sunitinib |
Capsule 25 mg |
Oral |
N |
- |
- |
- |
$1,170.80 |
$1,033.58 |
11.72% |
10% |
OWAPD |
Sunitinib |
Capsule 37.5 mg |
Oral |
N |
- |
- |
- |
$1,754.71 |
$1,549.06 |
11.72% |
10% |
OWAPD |
Sunitinib |
Capsule 50 mg |
Oral |
N |
- |
- |
- |
$2,370.50 |
$2,092.68 |
11.72% |
10% |
OWAPD |
Tacrolimus |
Capsule 0.5 mg |
Oral |
Y |
$63.14 |
N |
Y |
$63.14 |
$51.48 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 1 mg |
Oral |
Y |
$126.29 |
N |
Y |
$126.29 |
$102.96 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 1 mg (once daily prolonged release) |
Oral |
Y |
$75.78 |
N |
Y |
$75.78 |
$61.78 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 2 mg |
Oral |
Y |
$287.81 |
N |
Y |
$287.81 |
$234.65 |
18.47% |
10% |
GWAPD |
Tacrolimus |
Capsule 5 mg |
Oral |
Y |
$315.57 |
N |
Y |
$315.57 |
$257.28 |
18.47% |
10% |
GWAPD |
Tobramycin |
Solution for inhalation 300 mg in 5 mL |
Inhalation |
Y |
$416.76 |
N |
Y |
$416.76 |
$322.41 |
22.64% |
10% |
GWAPD |
Trastuzumab |
Powder for I.V. infusion 420 mg |
Injection |
Y |
$346.50 |
N |
Y |
$346.50 |
$298.41 |
13.88% |
10% |
OWAPD |
Trastuzumab |
Powder for I.V. infusion 60 mg |
Injection |
Y |
$58.09 |
N |
Y |
$58.09 |
$50.03 |
13.88% |
10% |
OWAPD |
Vancomycin |
Capsule 125 mg (125,000 I.U.) (as hydrochloride) |
Oral |
N |
- |
- |
- |
$50.69 |
$44.16 |
12.88% |
10% |
GWAPD |
Vancomycin |
Capsule 250 mg (250,000 I.U.) (as hydrochloride) |
Oral |
N |
- |
- |
- |
$101.36 |
$88.30 |
12.88% |
10% |
GWAPD |
Varenicline |
Box containing 11 tablets 0.5 mg and 42 tablets 1 mg |
Oral |
N |
- |
- |
- |
$51.66 |
$45.35 |
12.21% |
10% |
OWAPD |
Varenicline |
Tablet 1 mg |
Oral |
N |
- |
- |
- |
$60.90 |
$53.46 |
12.22% |
10% |
OWAPD |
Flow-on price disclosure reductions
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 April 2025 is available in the Pricing-Combination-Flow-on-Price-Reductions-FED-1-Apr-2025 (Excel 12KB). Sponsors are able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex‑manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2025 April cycle can be downloaded below.
- 2025 April PD cycle Confirmed Prices Report (excludes EFC drugs) (Excel 160KB) - (PDF 844KB)
- 2025 April PD cycle Confirmed Prices Report (EFC drugs) (Excel 20KB) - (PDF 472KB)
Brand price reductions and savings to patients
The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 April 2025. This information is made available to assist patients understand how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.
The brand price reductions report for the 2025 April cycle can be downloaded below.